Osimertinib with chemotherapy is approved by the USFDA for EGFR-mutated non-small cell lung cancer

Osimertinib with chemotherapy is approved by the USFDA for EGFR-mutated non-small cell lung cancer

Share This Post

The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) who have tumors with EGFR exon 19 deletions or exon 21 L858R mutations, as identified by an FDA-approved test, on February 16, 2024.

The test was done in FLAURA 2 (NCT04035486), a random, open-label study with 557 people who had either EGFR exon 19 deletion or exon 21 L858R mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and had not had any systemic treatment for advanced illness before. Patients were randomly assigned in a 1:1 ratio to receive either osimertinib plus platinum-based chemotherapy or osimertinib alone.

The primary efficacy measure was progression-free survival (PFS), evaluated by the investigator, with overall survival (OS) as a significant secondary measure. When osimertinib was combined with platinum-based chemotherapy, progression-free survival (PFS) was much higher than when osimertinib was used alone. The hazard ratio was 0.62 (95% CI: 0.49–0.79; two-sided p-value<0.0001). The median progression-free survival (PFS) was 25.5 months with a 95% confidence interval (CI) of 24.7 to not estimable (NE) in one arm, and 16.7 months with a 95% CI of 14.1 to 21.3 in the other arm.

Although the overall survival statistics were not fully developed at the current analysis, with just 45% of the pre-specified fatalities reported for the final analysis, there was no indication of a negative trend.

Leukopenia, thrombocytopenia, neutropenia, lymphopenia, rash, diarrhea, stomatitis, nail damage, dry skin, and high blood creatinine levels were some of the most common side effects that happened to people who were given osimertinib along with platinum-based chemotherapy.

The suggested osimertinib dosage is 80 mg taken orally once a day, with or without food, until disease progression or unacceptable toxicity. Consult the prescribing information for pemetrexed with cisplatin or carboplatin for the specific dose details.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Utilizing Immunotherapy to Treat Late-Stage Cancers
Immunotherapy

Utilizing Immunotherapy to Treat Late-Stage Cancers

  Introduction Immunotherapy has become a groundbreaking method in cancer treatment, especially for advanced-stage cancer treatments that have demonstrated minimal effectiveness with standard medicines. This

Outline: Understanding Survivorship in the Context of Advanced Cancers The Landscape of Long-Term Care for Advanced Cancer Patients Navigating the Emotional and Psychological Journey The Future of Care Coordination and Survivorship Plans
Cancer

Survivorship and long-term care in advanced cancers

Dive into the complexities of survivorship and long-term care for individuals facing advanced cancers. Discover the latest advancements in care coordination and the emotional journey of cancer survivorship. Join us as we explore the future of supportive care for metastatic cancer survivors.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy